Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Metastatic Breast Cancer
NCT00096434Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2004
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Proportion of confirmed tumor responses up to 5 years. Started Sep 2004; status: completed.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00096434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00096434.